Loading
A phase 1/2 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, active and no longer recruiting.
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) is a phase 1/2 interventional study registered as NCT03974022 by Dizal Pharmaceuticals, with 315 participants enrolled, started 2019-07-09 and due to reach its primary completion in 2024-07-29. Interventions recorded: Sunvozertinib. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
315 enrolled.
97.5% CI 33.6 to 58.5; Figures from the ClinicalTrials.gov results section (first posted 2025-12-03), not from a publication · 97.5% CI 34.8 to 57.0
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).primary | Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg | 85 | 45.9% | - | - | link |
| Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg | 107 | 45.8% |
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.